Lethal drug combination: Arsenic loaded multiple drug mesoporous silica for theranostic applications

Intrinsic and Stable Conjugation of Thiolated Mesoporous Silica Nanoparticles with Radioarsenic

“…Comparison of this value with the number of thiols per gram of thiolated MSN(5 nm pores) (0.4 mmol of –SH/g) shows that this corresponds to a 1:2 molar ratio of As:thiols, implying that at full capacity two sulfhydryl groups are binding to each arsenic atom. This ATO loading capacity is also notably lower than that reported by Wu et al of 120 mg/g 39 and Muhammad et al of 46 mg/g 36 for other thiolated MSN preparations, likely as a result of a lower surface area (580 m 2 /g vs 1021 m 2 /g for Wu et al and 728 m 2 /g for Muhammad et al) and thiol content (0.4 mmol of –SH/g vs 1.1 –SH/g for Wu et al) of the MSN used in this work. Despite this, a loading capacity of 20 mg of ATO per gram of MSN is sufficient to deliver therapeutic quantities of 0.1–1 mg of ATO/kg with MSN doses of <50 mg of MSN/kg, which have been shown to be safe in murine models.…”

“…Recent efforts to increase the therapeutic index of ATO have utilized a variety of nanoparticle-based drug delivery methods including liposomes, 28–31 polymeric nanoparticles, 32–35 and most recently mesoporous silica nanoparticles. 36–39 …”

New diamidequat-type surfactants in fabrication of long-sustained theranostic nanocapsules: Colloidal stability, drug delivery and bioimaging

“…[6,7]. The current stage of developing nanocarriers for drug delivery has allowed demonstrating combinations of some desired properties, i.e., the pharmaceutical nanocarriers combining different properties and allowing for multiple functions, for example longcirculating nanocarriers that might combine the ability to remain in the circulation for a long time along with the property to specifically accumulate in the targeted areas [8][9][10].…”

Zeolitic Imidazolate Framework‐8 as pH‐Sensitive Nanocarrier for “Arsenic Trioxide” Drug Delivery

“…They have been used to improvet he therapeutic effectso fa rsenic species in cancer therapy. [8][9][10] Despite the reported positive results of using nanocarriers for ATOd elivery,t he amounts of the carried drug were not too high with respect to the amount of the carrier materials used (see Ta ble 1). Moreover,t he ATOr elease from these nanocarriers was not well-definedt riggered or complete.…”